ClinicalTrials.gg
CompletedNCT02174731Updated Dec 16, 2019Results posted

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.

A Phase 3 interventional study of Roxadustat and Epoetin alfa in Anemia, sponsored by AstraZeneca. Completed at 189 sites in 18 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-12-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,133
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
2nd of 43
2,133 · median 154
Started
2014
with 4 others
Phase 3
25 of 43
1 open now
Registered
13th of 43
by date
Lead sponsor
3 of 43
AstraZeneca

Among the 43 studies testing roxadustat in Anemia, this one is the 2nd largest by enrollment, is one of 5 that started in 2014, is one of 25 in phase 3, and was the 13th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in chronic kidney disease patients on dialysis.

Read the detailed description

This is a Phase 3, multicenter, randomized, open-label, active-controlled study to evaluate the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in dialysis patients. Patients on hemodialysis (HD) or peritoneal dialysis (PD) who have been treated with an erythropoietin analogue or have an indication for treatment with an erythropoietin analogue will be evaluated for eligibility and randomized at a 1:1 ratio to treatment with roxadustat (with discontinuation of prior erythropoietin analogue therapy) or to an active-control group treated with epoetin alfa

03

Conditions studied

  • Anemia

Browse trials for

Keywords

  • Renal,
  • CKD,
  • Epoetin alfa,
  • Roxadustat,
  • dialysis,
  • anemia
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures
  2. Age ≥18 years at screening visit 1
  3. Previous versions of the protocol prior to US amendment ver 6.0 and outside of US amendment ver 7.0:

    Receiving or initiating hemodialysis or peritoneal dialysis for treatment of native kidney end-stage renal disease (ESRD) at least 30 days prior to visit 1. Patients treated with hemodialysis must have access consisting of an arteriovenous fistula, AV graft, or tunneled (permanent) catheter. Patients on peritoneal dialysis must have a functioning peritoneal dialysis catheter in place.

    Starting with US amendment ver. 6.0 and outside of US amendment ver 7.0 (changed to recruit incident dialysis patients only):

    Receiving or initiating hemodialysis or peritoneal dialysis for treatment of native kidney end-stage renal disease (ESRD) for a minimum of 2 weeks and a maximum of 4 months prior to randomization. Patients treated with hemodialysis must have access consisting of an arteriovenous fistula, AV graft, or tunneled (permanent) catheter. Patients on peritoneal dialysis must have a functioning peritoneal dialysis catheter in place.

  4. Two central laboratory values during the screening period, obtained at least 7 days apart, must be \<12 g/dL in patients currently treated with an erythropoietin analogue or \<10 g/dL in patients not currently treated with an erythropoietin analogue. Patients are considered not currently treated if they have not received either Mircera® for at least 8 weeks or any other erythropoietin analogue for at least 4 weeks prior to visit 1.
  5. Ferritin ≥100 ng/mL at randomization (obtained from screening visit)
  6. TSAT ≥20% at randomization (obtained from screening visit)
  7. Serum folate level ≥ lower limit of normal (LLN) at randomization (obtained from screening visit)
  8. Serum vitamin B12 level ≥ LLN at randomization (obtained from screening visit)
  9. (ALT) and aspartate aminotransferase (AST) ≤3x (ULN), and total (Tbili) ≤1.5 x ULN at randomization (obtained from screening visit)
  10. Body weight 45 to 160 kg (prescribed dry weight)

Exclusion criteria

Exclusion criteria:

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  2. Previous randomisation in the present study
  3. Class III or IV congestive heart failure at enrolment
  4. Myocardial infarction, acute coronary syndrome, stroke, seizure or a thrombotic/thromboembolic event (e.g., deep vein thrombosis or pulmonary embolism) within 12 weeks prior to randomization
  5. History of chronic liver disease (e.g., chronic infectious hepatitis, chronic auto-immune liver disease, cirrhosis or fibrosis of the liver)
  6. Known hereditary hematologic disease such as thalassemia, sickle cell anemia, a history of pure red cell aplasia or other known causes for anemia other than CKD
  7. Known and untreated retinal vein occlusion or known and untreated proliferative diabetic retinopathy (risk for retinal vein thrombosis)
  8. Diagnosis or suspicion (e.g. complex kidney cyst of Bosniak Category IIF, III or IV) of renal cell carcinoma on renal ultrasound (or other imaging procedure e.g. CT scan or MRI) conducted at screening or within 12 weeks prior to randomization.
  9. Uncontrolled hypertension at the time of randomization (defined as systolic BP ≥180 mmHg or diastolic BP ≥100 mmHg on repeated measurement post-dialysis in hemodialysis patients or at any time in peritoneal dialysis patients), to epoetin alfa treatment (e.g., pure red cell aplasia, or know inability to tolerate epoetin alfa)
  10. History of prostate cancer, breast cancer or any other , except the following: cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ or resected colonic polyps.
  11. Positive for any of the following: (HIV), surface antigen (HBsAg) or anti- virus antibody (anti-HCV Ab)
  12. Chronic inflammatory diseases such as rheumatoid arthritis, SLE, ankylosing spondylitis, psoriatic arthritis or inflammatory bowel disease that is determined to be the principal cause of anemia
  13. Known hemosiderosis, hemochromatosis or hypercoagulable condition
  14. Any prior organ transplant with the exception of an autologous renal transplant or a renal transplant that was subsequently removed ("explanted") or scheduled organ transplantation date
  15. Any red blood cell (RBC) transfusion during the screening period
  16. Any current condition leading to active significant blood loss
  17. Any prior treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
  18. Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within the month preceding the first administration of IP in this study. (Note: patients consented and screened, but not randomized in this study or a previous study are not excluded)
  19. History of alcohol or drug abuse within 2 years prior to randomization
  20. Females of , unless using as detailed in the protocol or sexual abstinence (see Section 3.8)
  21. Pregnant or breastfeeding females
  22. Known allergy to the product or any of its ingredients
  23. Any medical condition, including active, infection, that in the opinion of the investigator or Sponsor may pose a safety risk to a patient in this study, which may confound efficacy or safety assessment, or may interfere with study participation
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,133 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Drug: Roxadustat

  • Active comparator
    Epoetin alfa

    Drug: Epoetin alfa

Interventions

  • Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.

  • Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52

    Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation Analysis of Covariance (ANCOVA). Baseline Hb was used as a covariate and treatment group, cardiovascular (CV) history, geographic region and dialysis duration as fixed effects. The adjusted least squares (LS) mean estimates of change from baseline during Week 28 to Week 52 are presented.

    Time frame: Baseline (Day 1, Week 0), Week 28 to 52

Secondary outcomes

  1. Change in Hb From Baseline to the Mean Level During the Evaluation Period (Week 28 to Week 36) Without Having Received Rescue Therapy Within 6 Weeks Prior to and During the 8-Week Evaluation Period

    Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 36,without having received rescue therapy within 6 weeks prior to and during this 8 week evaluation period was analysed using Mixed Model of Repeated Measures (MMRM). Baseline Hb was used as a covariate and treatment group, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline during Week 28 to Week 36 are presented for participants that did not receive rescue therapy within 6 weeks prior to and during this 8-week evaluation period.

    Time frame: Baseline (Day 1, Week 0), Week 28 to 36

  2. Proportion of Total Time of Hb Within the Interval of >=10 g/dL From Week 28 to Week 52

    The proportion of total time was computed as follows: For each participant, the recorded Hb values were first linearly interpolated between measurements. The time this interpolated curve was \>=10 g/dL was computed and subsequently divided by the time between the measurements from Week 28 to Week 52. The difference between roxadustat and epoetin alfa were compared using ANCOVA. Baseline Hb was used as a covariate and the treatment groups, CV history, geographic region and dialysis duration as fixed effects.

    Time frame: Week 28 to 52

  3. Proportion of Total Time of Hb Within the Interval of 10 to 12 g/dL From Week 28 to Week 52

    The proportion of total time was computed as follows: For each participant, the recorded Hb values were first linearly interpolated between measurements. The time this interpolated curve was within 10-12 g/dL was computed and subsequently divided by the time between the measurement from Week 28 to 52. The difference between roxadustat and epoetin alfa were compared using ANCOVA. Baseline Hb was used as a covariate and the treatment groups, CV history, geographic region and dialysis duration as fixed effects.

    Time frame: Week 28 to 52

  4. Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24

    Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analysed using ANCOVA. Baseline Hb and baseline LDL were used as covariates and treatment groups, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.

    Time frame: Baseline (Day 1, Week 0) to Week 24

  5. Mean Change in Hb From Baseline to the Participant's Mean Level Between Week 28 to Week 52 in Participants With Baseline High-Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)

    Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb is defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Changes in Hb from baseline to mean value during Weeks 28 to 52 in participants with baseline hsCRP \>ULN was analyzed using a MAR based multiple imputation ANCOVA. Baseline Hb was used as a covariate and treatment group, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline during Week 28 to Week 52 are presented.

    Time frame: Baseline (Day 1, Week 0), Week 28 to 52

  6. Mean Monthly IV Iron Use From Week 36 to End of Study (EOS)

    Oral iron supplementation was allowed for both treatment groups without restriction. Oral iron was recommended for dietary supplementation to support erythropoiesis and as the first line treatment for prevention and treatment of iron deficiency, unless the participant was intolerant to this route of treatment. In participants receiving roxadustat, the Investigator was allowed to initiate the use of an approved IV iron supplement if a participant's Hb value had not sufficiently responded to 2 or more dose increases of the IP, and ferritin \<100 nanogram per milliliter (ng/mL) or transferrin saturation (TSAT) \<20%. IP treatment was allowed to continue during IV iron administration. Discontinuation of IV iron supplementation was recommended once the participant was no longer considered to be iron deficient (ferritin \>100 ng/mL and TSAT \>20%).

    Time frame: Week 36 to EOS (4 weeks after the treatment period)

  7. Time-To-First Administration of RBC Transfusion as Rescue Therapy

    Time-to-first RBC transfusion as rescue therapy was calculated as (date of first occurrence of any RBC transfusion as rescue therapy, or date of censoring if no event had occurred) - (date of first dose of IP) + 1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.

    Time frame: Baseline (Day 1, Week 0) up to EOS (4 weeks after the treatment period)

07

Results

Posted Dec 16, 2019
Limitations and caveats
27 participants were excluded from the analysis due to Good Clinical Practice violations or system technical issues (17 in the roxadustat group and 10 in the epoetin alfa group).

Participant flow

This study was conducted at 197 centers in 18 countries worldwide across the United States (US), Canada, Latin America, Australia, Asia and Europe between 01 July 2014 and 26 September 2018. Participants with chronic kidney disease (CKD) who were on dialysis were recruited in this study.

Participant flow — Overall Study
MilestoneRoxadustatEpoetin Alfa
Started10511055
Received treatment10481053
Completed982990
Not completed6965
Withdrew: Participant decision6764
Withdrew: Incorrect enrolment before randomization01
Withdrew: Missing20

Outcome measures

PrimaryMean Change From Baseline in Hb Averaged Over Week 28 to Week 52

Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation Analysis of Covariance (ANCOVA). Baseline Hb was used as a covariate and treatment group, cardiovascular (CV) history, geographic region and dialysis duration as fixed effects. The adjusted least squares (LS) mean estimates of change from baseline during Week 28 to Week 52 are presented.

Time frame:
Baseline (Day 1, Week 0), Week 28 to 52
Reported as:
Least squares mean · g/dL
Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52
g/dLRoxadustatEpoetin Alfa
Mean Change From Baseline in Hb Averaged Over Week 28 to Week 520.77 ± 0.0410.68 ± 0.040
Statistical analysis
  • Roxadustat vs Epoetin Alfa · ANCOVA · p = <0.001 · Least square mean difference: 0.09 · 95% CI 0.01 to 0.18Difference between groups (roxadustat minus Epoetin alfa) in LS mean changes.
SecondaryChange in Hb From Baseline to the Mean Level During the Evaluation Period (Week 28 to Week 36) Without Having Received Rescue Therapy Within 6 Weeks Prior to and During the 8-Week Evaluation Period

Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 36,without having received rescue therapy within 6 weeks prior to and during this 8 week evaluation period was analysed using Mixed Model of Repeated Measures (MMRM). Baseline Hb was used as a covariate and treatment group, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline during Week 28 to Week 36 are presented for participants that did not receive rescue therapy within 6 weeks prior to and during this 8-week evaluation period.

Time frame:
Baseline (Day 1, Week 0), Week 28 to 36
Reported as:
Least squares mean · g/dL
Change in Hb From Baseline to the Mean Level During the Evaluation Period (Week 28 to Week 36) Without Having Received Rescue Therapy Within 6 Weeks Prior to and During the 8-Week Evaluation Period
g/dLRoxadustatEpoetin Alfa
Change in Hb From Baseline to the Mean Level During the Evaluation Period (Week 28 to Week 36) Without Having Received Rescue Therapy Within 6 Weeks Prior to and During the 8-Week Evaluation Period0.88 ± 0.0440.74 ± 0.043
Statistical analysis
  • Roxadustat vs Epoetin Alfa · MMRM · p = <0.001 · Least square mean difference: 0.14 · 95% CI 0.03 to 0.25Difference between groups (roxadustat minus Epoetin alfa) in LS mean change.
SecondaryProportion of Total Time of Hb Within the Interval of >=10 g/dL From Week 28 to Week 52

The proportion of total time was computed as follows: For each participant, the recorded Hb values were first linearly interpolated between measurements. The time this interpolated curve was \>=10 g/dL was computed and subsequently divided by the time between the measurements from Week 28 to Week 52. The difference between roxadustat and epoetin alfa were compared using ANCOVA. Baseline Hb was used as a covariate and the treatment groups, CV history, geographic region and dialysis duration as fixed effects.

Time frame:
Week 28 to 52
Reported as:
Least squares mean · proportion of total time
Proportion of Total Time of Hb Within the Interval of >=10 g/dL From Week 28 to Week 52
proportion of total timeRoxadustatEpoetin Alfa
Proportion of Total Time of Hb Within the Interval of >=10 g/dL From Week 28 to Week 520.79 ± 0.0120.76 ± 0.012
Statistical analysis
  • Roxadustat vs Epoetin Alfa · ANCOVA · p = <0.001 · Least square mean difference: 0.03 · 95% CI 0.00 to 0.05Difference between groups (roxadustat minus Epoetin alfa) in LS mean.
SecondaryProportion of Total Time of Hb Within the Interval of 10 to 12 g/dL From Week 28 to Week 52

The proportion of total time was computed as follows: For each participant, the recorded Hb values were first linearly interpolated between measurements. The time this interpolated curve was within 10-12 g/dL was computed and subsequently divided by the time between the measurement from Week 28 to 52. The difference between roxadustat and epoetin alfa were compared using ANCOVA. Baseline Hb was used as a covariate and the treatment groups, CV history, geographic region and dialysis duration as fixed effects.

Time frame:
Week 28 to 52
Reported as:
Least squares mean · proportion of total time
Proportion of Total Time of Hb Within the Interval of 10 to 12 g/dL From Week 28 to Week 52
proportion of total timeRoxadustatEpoetin Alfa
Proportion of Total Time of Hb Within the Interval of 10 to 12 g/dL From Week 28 to Week 520.65 ± 0.0130.63 ± 0.012
Statistical analysis
  • Roxadustat vs Epoetin Alfa · ANCOVA · p = <0.001 · Least square mean difference: 0.02 · 95% CI -0.01 to 0.05Difference between groups (roxadustat minus Epoetin alfa) in LS mean.
SecondaryMean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24

Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analysed using ANCOVA. Baseline Hb and baseline LDL were used as covariates and treatment groups, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.

Time frame:
Baseline (Day 1, Week 0) to Week 24
Reported as:
Least squares mean · millimole per liter
Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24
millimole per literRoxadustatEpoetin Alfa
Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24-0.38 ± 0.026-0.05 ± 0.026
Statistical analysis
  • Roxadustat vs Epoetin Alfa · ANCOVA · p = <0.001 · Least square mean difference: -0.33 · 95% CI -0.39 to -0.27Difference between groups (roxadustat minus Epoetin alfa) in LS mean.
SecondaryMean Change in Hb From Baseline to the Participant's Mean Level Between Week 28 to Week 52 in Participants With Baseline High-Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)

Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb is defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Changes in Hb from baseline to mean value during Weeks 28 to 52 in participants with baseline hsCRP \>ULN was analyzed using a MAR based multiple imputation ANCOVA. Baseline Hb was used as a covariate and treatment group, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline during Week 28 to Week 52 are presented.

Time frame:
Baseline (Day 1, Week 0), Week 28 to 52
Reported as:
Least squares mean · g/dL
Mean Change in Hb From Baseline to the Participant's Mean Level Between Week 28 to Week 52 in Participants With Baseline High-Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)
g/dLRoxadustatEpoetin Alfa
Mean Change in Hb From Baseline to the Participant's Mean Level Between Week 28 to Week 52 in Participants With Baseline High-Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)0.80 ± 0.0770.59 ± 0.076
Statistical analysis
  • Roxadustat vs Epoetin Alfa · ANCOVA · p = <0.001 · Least square mean difference: 0.20 · 95% CI 0.04 to 0.36Difference between groups (roxadustat minus Epoetin alfa) in LS mean.
SecondaryMean Monthly IV Iron Use From Week 36 to End of Study (EOS)

Oral iron supplementation was allowed for both treatment groups without restriction. Oral iron was recommended for dietary supplementation to support erythropoiesis and as the first line treatment for prevention and treatment of iron deficiency, unless the participant was intolerant to this route of treatment. In participants receiving roxadustat, the Investigator was allowed to initiate the use of an approved IV iron supplement if a participant's Hb value had not sufficiently responded to 2 or more dose increases of the IP, and ferritin \<100 nanogram per milliliter (ng/mL) or transferrin saturation (TSAT) \<20%. IP treatment was allowed to continue during IV iron administration. Discontinuation of IV iron supplementation was recommended once the participant was no longer considered to be iron deficient (ferritin \>100 ng/mL and TSAT \>20%).

Time frame:
Week 36 to EOS (4 weeks after the treatment period)
Reported as:
Mean · milligram per month
Mean Monthly IV Iron Use From Week 36 to End of Study (EOS)
milligram per monthRoxadustatEpoetin Alfa
Mean Monthly IV Iron Use From Week 36 to End of Study (EOS)58.71 ± 236.1291.37 ± 225.64
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Wilcoxon Rank Sum Test · p = <0.0001
SecondaryTime-To-First Administration of RBC Transfusion as Rescue Therapy

Time-to-first RBC transfusion as rescue therapy was calculated as (date of first occurrence of any RBC transfusion as rescue therapy, or date of censoring if no event had occurred) - (date of first dose of IP) + 1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.

Time frame:
Baseline (Day 1, Week 0) up to EOS (4 weeks after the treatment period)
Reported as:
Number · events per 100 participant years
Time-To-First Administration of RBC Transfusion as Rescue Therapy
events per 100 participant yearsRoxadustatEpoetin Alfa
Time-To-First Administration of RBC Transfusion as Rescue Therapy6.07.2
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.83 · 95% CI 0.64 to 1.07

Adverse events

Collected over From the first dose of IP administration (Day 1, Week 0) to 28 days after the last administration of the IP, with treatment duration up to 4 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roxadustat247/1,048 (23.6%)604/1,048 (57.6%)391/1,048 (37.3%)
Epoetin Alfa231/1,053 (21.9%)606/1,053 (57.5%)360/1,053 (34.2%)
Most frequent serious events
Showing 10 of 771
Most frequent serious events
EventRoxadustatEpoetin Alfa
PneumoniaInfections and infestations70/104878/1053
Acute myocardial infarctionCardiac disorders39/104841/1053
SepsisInfections and infestations40/104840/1053
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications37/104831/1053
Hypertensive crisisVascular disorders24/104836/1053
Fluid overloadMetabolism and nutrition disorders32/104829/1053
Hypertensive emergencyVascular disorders24/104831/1053
Cardiac failure congestiveCardiac disorders24/104829/1053
HyperkalaemiaMetabolism and nutrition disorders27/104821/1053
PeritonitisInfections and infestations24/104824/1053
Most frequent other events
Most frequent other events
EventRoxadustatEpoetin Alfa
DiarrhoeaGastrointestinal disorders114/1048101/1053
HypertensionVascular disorders85/104885/1053
HeadacheNervous system disorders79/104856/1053
Upper respiratory tract infectionInfections and infestations70/104854/1053
NauseaGastrointestinal disorders61/104865/1053
HypotensionVascular disorders64/104854/1053
CoughRespiratory, thoracic and mediastinal disorders61/104862/1053
BronchitisInfections and infestations43/104861/1053
VomitingGastrointestinal disorders60/104852/1053

Baseline characteristics

The Intention-To-Treat (ITT) analysis set included all participants who were randomized to investigational product (IP) irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.

Age, Continuous
Age, Continuous(years)RoxadustatEpoetin AlfaTotal
Mean53.5 ± 15.3054.5 ± 14.9754.0 ± 15.14
Sex: Female, Male
Sex: Female, Male(Participants)RoxadustatEpoetin AlfaTotal
Female426429855
Male6256261251
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RoxadustatEpoetin AlfaTotal
Hispanic or Latino268271539
Not Hispanic or Latino7837841567
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RoxadustatEpoetin AlfaTotal
White5975981195
Black of African American148158306
Asian208198406
Native Hawaiian or other Pacific Islander538
American Indian or Alaska Native5062112
Other433679
08

Study locations

189 sites
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    El Centro, California 92243, United States
  • Research Site
    Fairfield, California 94534, United States
  • Research Site
    Glendale, California 91205, United States
  • Research Site
    Long Beach, California 90802, United States
  • Research Site
    Long Beach, California 90807, United States
  • Research Site
    Los Angeles, California 90022, United States
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Lynwood, California 90262, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Ontario, California 91762, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Riverside, California 92503, United States
  • Research Site
    Sacramento, California 95825, United States
  • Research Site
    Sun Valley, California 91352, United States
  • Research Site
    Whittier, California 90602, United States
  • Research Site
    Whittier, California 90606, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Miami Gardens, Florida 33169, United States
  • Research Site
    River Forest, Illinois 60305, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Baton Rouge, Louisiana 70808, United States
  • Research Site
    Lanham, Maryland 20706, United States
  • Research Site
    Plymouth, Massachusetts 02360, United States
  • Research Site
    Roseville, Michigan 48066, United States
  • Research Site
    Gulfport, Mississippi 39501, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Reno, Nevada 89511, United States
  • Research Site
    Paterson, New Jersey 07504, United States
  • Research Site
    Bronx, New York 10461, United States
  • Research Site
    Great Neck, New York 11021, United States
  • Research Site
    Orchard Park, New York 14127, United States
  • Research Site
    Asheville, North Carolina 28805, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Cincinnati, Ohio 45206, United States
  • Research Site
    Shawnee, Oklahoma 74804, United States
  • Research Site
    Bethlehem, Pennsylvania 18017, United States
  • Research Site
    Philadelphia, Pennsylvania 19106, United States
  • Research Site
    East Providence, Rhode Island 02914, United States
  • Research Site
    Austin, Texas 78756, United States
  • Research Site
    Austin, Texas 78758, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77091, United States
  • Research Site
    San Antonio, Texas 78212, United States
  • Research Site
    San Antonio, Texas 78222, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Newport News, Virginia 23605, United States
  • Research Site
    Sterling, Virginia 20164, United States
  • Research Site
    Bluefield, West Virginia 24701, United States
  • Research Site
    Camperdown, 2050, Australia
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Concord, 2139, Australia
  • Research Site
    Launceston, 7250, Australia
  • Research Site
    Prahan, 3004, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Wahroonga, 2076, Australia
  • Research Site
    Botevgrad, 2140, Bulgaria
  • Research Site
    Dupnitsa, 2600, Bulgaria
  • Research Site
    Gotse Delchev, 2900, Bulgaria
  • Research Site
    Haskovo, 6300, Bulgaria
  • Research Site
    Razlog, 2760, Bulgaria
  • Research Site
    Samokov, 2000, Bulgaria
  • Research Site
    Sandanski, 2800, Bulgaria
  • Research Site
    Shumen, 9700, Bulgaria
  • Research Site
    Silistra, Bulgaria
  • Research Site
    Sliven, 8800, Bulgaria
  • Research Site
    Smolyan, 3700, Bulgaria
  • Research Site
    Yambol, 8600, Bulgaria
  • Research Site
    Edmonton, Alberta T6G 2B7, Canada
  • Research Site
    Kamloops, British Columbia V2C 2T1, Canada
  • Research Site
    Saint John, New Brunswick E2L 4L2, Canada
  • Research Site
    Sydney, Nova Scotia B1P 1P3, Canada
  • Research Site
    Brampton, Ontario L6R 3J7, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
  • Research Site
    Scarborough, Ontario M1P 2V5, Canada
  • Research Site
    Toronto, Ontario M3M 0B2, Canada
  • Research Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Research Site
    Montreal, Quebec H2X 3J4, Canada
  • Research Site
    Montreal, Quebec H4J 1C5, Canada
  • Research Site
    Quebec, G1R 2J6, Canada
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Praha 4, 140 00, Czechia
  • Research Site
    Praha 4, 140 21, Czechia
  • Research Site
    Praha, 190 61, Czechia
  • Research Site
    Rychnov nad Kneznou, 516 01, Czechia
  • Research Site
    Slany, 274 01, Czechia
  • Research Site
    Tabor, 390 03, Czechia
  • Research Site
    Usti nad Labem, 401 13, Czechia
  • Research Site
    Ajka, 8400, Hungary
  • Research Site
    Budapest, 1076, Hungary
  • Research Site
    Budapest, 1077, Hungary
  • Research Site
    Budapest, 1097, Hungary
  • Research Site
    Debrecen, 4043, Hungary
  • Research Site
    Miskolc, 3526, Hungary
  • Research Site
    Nagykanizsa, 8800, Hungary
  • Research Site
    Székesfehérvár, 8000, Hungary
  • Research Site
    Tatabánya, 2800, Hungary
  • Research Site
    Chennai, 600006, India

Showing the first 100 of 189 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Fishbane S, Pollock CA, El-Shahawy M, Escudero ET, Rastogi A, Van BP, Frison L, Houser M, Pola M, Little DJ, Guzman N, Pergola PE. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study. J Am Soc Nephrol. 2022 Apr;33(4):850-866. doi: 10.1681/ASN.2020111638. PubMed 35361724 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Sep 2018, 50 months.

Results were first posted in Dec 2019, 1 year 2 months after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 50 months is above that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2014
First posted
Jun 25, 2014
StartActual
Jul 1, 2014
Primary completionActual
Sep 26, 2018
CompletionActual
Sep 26, 2018
Results first posted
Dec 16, 2019
Last update
Dec 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02174731
Lead sponsor
AstraZeneca
Collaborators
FibroGen
Responsible party
Sponsor
First posted
Jun 25, 2014
Start date
Jul 1, 2014
Primary completion
Sep 26, 2018
Completion
Sep 26, 2018
Results posted
Dec 16, 2019
Last update
Dec 16, 2019

Study contacts

Steven Fishbane, MD
principal investigator · Chief Division of Kidney Diseases and Hypertension, North Shore University Hospital, Great Neck, NY, USA
Mark Houser, MD
study director · AZ R&D, Gaithersburg, USA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion